See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Outcomes of patients with Stenotrophomonas maltophilia infections treated with cefiderocol: PROVE (Retrospective Cefiderocol Chart Review) Study
Outcomes of patients with Stenotrophomonas maltophilia infections treated with cefiderocol: PROVE (Retrospective Cefiderocol Chart Review) Study
Pharmacokinetics, safety, and tolerability of ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, in participants with hepatic impairment
Pharmacokinetics, safety, and tolerability of ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2, in participants with hepatic impairment
Phenotyping and genotyping analysis using baseline swab samples in ensitrelvir clinical studies
Phenotyping and genotyping analysis using baseline swab samples in ensitrelvir clinical studies
Population pharmacokinetic analysis of ensitrelvir, an inhibitor of 3C-like (3CL) protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for patients with SARS-CoV-2 infection
Population pharmacokinetic analysis of ensitrelvir, an inhibitor of 3C-like (3CL) protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for patients with SARS-CoV-2 infection
Pre-exposure prophylactic treatment with ensitrelvir inhibited SARS-CoV-2 infection in hamster aerosol transmission model
Pre-exposure prophylactic treatment with ensitrelvir inhibited SARS-CoV-2 infection in hamster aerosol transmission model
Prediction of drug-drug interaction of ensitrelvir as CYP3A substrate using physiologically-based pharmacokinetic model
Prediction of drug-drug interaction of ensitrelvir as CYP3A substrate using physiologically-based pharmacokinetic model
You Are Viewing Congress Locations
ESCMID 2025
CROI 2025
SCCM 2025
IDWeek 2024
NACFC 2024
IAS 2024
ESCMID 2024
SCCM 2024
IDWeek 2023
CHEST 2023
ESWI 2023
ISSX 2023
PAGE 2023
